The 'race to zero' isn't just a clinical vanity metric; it’s a biological imperative to stay ahead of the resistance curve. Faster, deeper biochemical response correlates with better survival percentages at the two and four-year marks.
Zytiga (Abiraterone acetate) and Erleada (Apalutamide) function through distinct mechanisms within prostate cancer pharmacology. Zytiga is a CYP17 enzyme inhibitor that blocks androgen biosynthesis in the testes, adrenal glands, and tumor tissues. In contrast, Erleada is a competitive androgen receptor inhibitor that prevents nuclear translocation and DNA binding. Understanding these pathways is essential for medical students evaluating treatment strategies for castration-resistant prostate cancer.
In clinical oncology, Zytiga (Abiraterone acetate) is co-administered with prednisone to manage the compensatory increase in adrenocorticotropic hormone (ACTH). Because Zytiga inhibits the CYP17 enzyme, it reduces cortisol production, which can lead to mineralocorticoid excess. Erleada (Apalutamide) does not require concurrent steroid use for its primary mechanism, representing a key clinical distinction for students studying patient management and side effect profiles.
Both medications are utilized in the management of advanced prostate cancer, but their specific clinical indications can vary. Zytiga is frequently used for metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer. Erleada is often indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer. Medical students should review the latest clinical trial data to understand how these indications influence prescribing patterns.
From Columbia University alumni built in San Francisco
"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."
"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."
"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."
"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."
"Reading used to feel like a chore. Now it’s just part of my lifestyle."
"Feels effortless compared to reading. I’ve finished 6 books this month already."
"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."
"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."
"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"
"It is great for me to learn something from the book without reading it."
"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."
"Makes me feel smarter every time before going to work"
From Columbia University alumni built in San Francisco
